GlaxoSmithKline and Germany’s CureVac say they plan to collaborate on a new generation of vaccines targeting emerging variants of COVID-19.The announcement comes as public health experts around the world raise concerns about mutations in the virus that may make existing vaccines less effective.Also Read | The Finance Commission doesn’t rock the federal boat“The increase in emerging variants with the potential to reduce the efficacy of first generation COVID-19 vaccines requires acceleration of efforts to develop vaccines against new variants to keep one step ahead of the pandemic,’’ the companies said in a statement Wednesday. “These next generation COVID-19 vaccines may either be used to protect people who have not been vaccinated before,.